EP0748338A4 - Maturation d'anticorps in vitro par affinite utilisant la mutagenese par balayage a l'alanine - Google Patents

Maturation d'anticorps in vitro par affinite utilisant la mutagenese par balayage a l'alanine

Info

Publication number
EP0748338A4
EP0748338A4 EP95911994A EP95911994A EP0748338A4 EP 0748338 A4 EP0748338 A4 EP 0748338A4 EP 95911994 A EP95911994 A EP 95911994A EP 95911994 A EP95911994 A EP 95911994A EP 0748338 A4 EP0748338 A4 EP 0748338A4
Authority
EP
European Patent Office
Prior art keywords
affinity maturation
alanine scanning
scanning mutagenesis
antibody affinity
vitro antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95911994A
Other languages
German (de)
English (en)
Other versions
EP0748338A1 (fr
Inventor
Craig M Lewis
Steven W Ludmerer
Gregory F Hollis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0748338A1 publication Critical patent/EP0748338A1/fr
Publication of EP0748338A4 publication Critical patent/EP0748338A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP95911994A 1994-03-04 1995-02-27 Maturation d'anticorps in vitro par affinite utilisant la mutagenese par balayage a l'alanine Withdrawn EP0748338A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20607994A 1994-03-04 1994-03-04
US206079 1994-03-04
PCT/US1995/002492 WO1995023813A1 (fr) 1994-03-04 1995-02-27 Maturation d'anticorps in vitro par affinite utilisant la mutagenese par balayage a l'alanine

Publications (2)

Publication Number Publication Date
EP0748338A1 EP0748338A1 (fr) 1996-12-18
EP0748338A4 true EP0748338A4 (fr) 2001-03-28

Family

ID=22764890

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95911994A Withdrawn EP0748338A4 (fr) 1994-03-04 1995-02-27 Maturation d'anticorps in vitro par affinite utilisant la mutagenese par balayage a l'alanine

Country Status (4)

Country Link
EP (1) EP0748338A4 (fr)
JP (1) JPH09509835A (fr)
CA (1) CA2183550A1 (fr)
WO (1) WO1995023813A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CZ292465B6 (cs) 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6025158A (en) * 1997-02-21 2000-02-15 Genentech, Inc. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
DK0968291T3 (da) 1997-02-21 2004-06-07 Genentech Inc Antistoffragment-polymerkonjugater
DE19728697C1 (de) * 1997-07-04 1999-03-25 Deutsches Krebsforsch Humaner Antikörper gegen ein Fusions(poly)peptid bzw. -protein, das einen Anteil von mindestens sechs Histidinen aufweist
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US7005504B2 (en) 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
CA2385745C (fr) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
ATE466085T1 (de) 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
BRPI0412007A (pt) * 2003-06-27 2006-08-15 Bioren Inc mutagênese look-through
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
EP2500037A3 (fr) 2005-05-16 2012-10-24 Abbott Biotechnology Ltd Utilisation d'un inhibiteur de TNF alpha pour traiter la polyarthrite érosive
RU2466740C2 (ru) 2006-04-05 2012-11-20 Эбботт Байотекнолоджи Лтд. Очистка антитела
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2008063213A2 (fr) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
CA2711984A1 (fr) 2008-01-15 2009-07-23 Abbott Gmbh & Co. Kg Composition de proteine pulverisee et procedes de fabrication de celle-ci
US9127052B2 (en) 2010-06-29 2015-09-08 Centre National De La Recherche Scientifique LLT-1 antibodies with new functional properties
EA201370076A1 (ru) * 2010-09-22 2013-08-30 Амген Инк. Иммуноглобулины-переносчики и их применение
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
WO2013158279A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de purification de protéines pour réduire des espèces acides
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
WO2015051293A2 (fr) 2013-10-04 2015-04-09 Abbvie, Inc. Utilisation d'ions métalliques pour moduler les profils de glycosylation des protéines dans le cas de protéines recombinées
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (fr) 2013-11-15 2015-05-21 Abbvie, Inc. Compositions de protéines de liaison génétiquement glycomodifiées

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CRAIG M. LEWIS ET AL: "Use of alanine scanning mutagenesis to improve the affinity of an anti-gp120 (HIV)antibody", JOURNAL OF CELLULAR BIOCHEMISTRY, SUPPLEMENT - KEYSTONE SYMPOSIUM ON ANTIBODY ENGINEERING, vol. 32, 7 March 1994 (1994-03-07) - 13 March 1994 (1994-03-13), XP000943396 *
LISA K. DENZIN ET AL.: "Mutational analysis of active site contact residues in anti-fluorescein monoclonal antibody", MOLECULAR IMMUNOLOGY, vol. 30, no. 15, 1993, pages 1331 - 1345, XP000943436 *
MIROSLAW K. GORNY ET AL.: "Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type I", JOURNAL OF VIROLOGY, vol. 68, no. 12, 15 December 1994 (1994-12-15), pages 8312-8320, XP000943394 *
ROBERT F. KELLEY AND MARK P. O'CONNELL: "Thermodynamic analysis of an antibody functional epitope", BIOCHEMISTRY, vol. 32, 1993, pages 6828 - 6835, XP000943393 *
See also references of WO9523813A1 *

Also Published As

Publication number Publication date
WO1995023813A1 (fr) 1995-09-08
JPH09509835A (ja) 1997-10-07
CA2183550A1 (fr) 1995-09-08
EP0748338A1 (fr) 1996-12-18

Similar Documents

Publication Publication Date Title
EP0748338A4 (fr) Maturation d'anticorps in vitro par affinite utilisant la mutagenese par balayage a l'alanine
PL330111A1 (en) Concentyratyed antibody preparation
ZA97257B (en) Anti-cd18 antibodies in stroke
EG24292A (en) Interferon conjugates
HU9602224D0 (en) Hematopoietic protein and materials and methods for making it
GB9009549D0 (en) Recombinant antibody and method
DE69732623D1 (en) Analogsignalmultiplexer in strombetriebsart
IL125548A0 (en) Cardiotrophin and uses therefor
EP0870828A4 (fr) Nouveau polypeptidetire de hemophilus paragallinarum et son procede de production
GB9425624D0 (en) Improvements in two stroke engines
GB2311584B (en) Improvement in seals
GB9402906D0 (en) Improvements in swatches
GB2311874B (en) Improvements in scrollers
GB9608937D0 (en) Screening methods for therapeutics and peptides used in the screen
EP0759034A4 (fr) Peptides a usage diagnostique et therapeutique
GB2287504B (en) Improvements in cockspur handles
AU125930S (en) Pedestal
GB9612813D0 (en) Improvements in chairs
TW306649U (en) Motion mechanism in scanner
GB9420875D0 (en) Improvements in mould making
GB9420892D0 (en) Recombinant antibodies
GB9411007D0 (en) Improvements in flylines
GB9419088D0 (en) Windbreak
CA74970S (en) Videophone base
GB9403188D0 (en) Improvements in canopies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961004

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010212

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020901